Republicans largely praised the HHS secretary’s track record during a marathon of House hearings last week, but some raised ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Patients who'd seen substantial hair regrowth in the first part of Nektar’s trial had a "deepening" treatment response, ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

Featured at this year’s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and ...

Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.

The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement ...

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” ...

The estimated 6,000 women a day who reach menopause experience it differently. Some have debilitating, vasomotor symptoms ...

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, ...

Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into ...